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Abstract
Background: Bacterial multidrug resistance (MDR) constitutes a major hurdle in the treatment of infectious
diseases worldwide. The present study was designed to evaluate the antibacterial activities of synthetic
p-toluenesulfonyl-hydrazinothiazoles against multidrug resistant Gram-negative bacteria.
Methods: The broth microdilution method was used to determine the minimal inhibitory concentrations (MIC).
Results: The results demonstrated that the best activities were obtained with hydrazinoselenazoles. p-Chloro-
benzyliden-selenosemicarbazide, 4-methyl-2-[(4-chloro-benzyliden)-hydrazinyl]-1,3-selenazole, p-chloro-benzoyl-
selenosemicarbazide and 4-chloromethyl-2-[(4-chlorobenziliden)-N-acetyl-hydrazinyl]-1,3-selenazole were more active
than the choramphenicol on Klebsiella pneumoniae KP63. Tested alone, the lowest MIC value of 16 mg/L was obtained
with p-methoxy-benzyliden-selenosemicarbazide against Enterobacter aerogenes ATCC13048, K. pneumoniae ATCC112296
and KP55. Tested in the presence of an efflux pump inhibitor, phenylalanine arginine β-naphthylamide (PAβN), the activity
of p-chloro-benzyliden-selenosemicarbazide, 4-methyl-2-[(4-chloro-benzyliden)-hydrazinyl]-1,3-selenazole, p-
chloro-benzoyl-selenosemicarbazide and p-methoxy-benzyliden-selenosemicarbazide significantly increased
with MIC values below 10 mg/L obtained respectively on 43.8 %, 31.3 %, 62.5 % and 100 % of the 16
tested bacterial strains. The lowest MIC value of 0.5 mg/L in the presence of PAβN was recorded with
p-chloro-benzoyl-selenosemicarbazide against Escherichia coli ATCC8739 and KP55 as well as p-methoxy-
benzyliden-selenosemicarbazide against E. aerogenes KP55. p-Chloro-benzyliden-selenosemicarbazide and
p-chloro-benzoyl-selenosemicarbazide contained the same pharmacophore as p-methoxy-benzyliden-
selenosemicarbazide.
Conclusion: This study indicates that p-chloro-benzyliden-selenosemicarbazide, p-chloro-benzoyl-selenosemicarbazide
and p-methoxy-benzyliden-selenosemicarbazide could be explored more to develop novel antimicrobial drugs to fight
MDR bacterial infections.
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Background
Bacterial multidrug resistance (MDR) constitutes a
major hurdle in the treatment of infectious diseases
worldwide. Bacterial efflux systems, especially AcrAB-
TolC pumps in Enterobacteriaceae or MexAB-OprM in
Pseudomonas aeruginosa, are involved in multidrug re-
sistance of pathogenic Gram-negative bacteria [1–5].
Clinically, the continuous emergence of Gram-negative
MDR bacteria drastically reduces the efficacy of the
antibiotic arsenal leading globally to an increase of the
frequency of therapeutic failure [6]. Consequently, new
antibacterials are needed to fight these bacterial patho-
gens, but progress in developing them has been slow [7].
p-Toluenesulfonyl-hydrazinothiazoles and hydrazinosele-
nazoles are synthetic compounds with established anti-
cancer, analgesic and anti-inflammatory activities [8–11].
The aim of the present work was to determine the anti-
bacterial activities of a panel of p-toluenesulfonyl-hydra-
zinothiazoles and hydrazinoselenazoles against different
bacterial strains expressing MDR phenotype. Further-
more, we highlighted possible pharmacophoric cores
amongst the active compounds.
Methods
Chemicals for antimicrobial assay
Chloramphenicol ≥ 98 % (Sigma-Aldrich, St. Quentin
Fallavier, France) was used as reference antibiotics (RA)
against the tested bacteria. p-iodonitrotetrazolium chlor-
ide (INT) and phenylalanine arginine β-naphthylamide
(PAβN) were used as microbial growth indicator and
efflux pumps inhibitor (EPI) respectively [12, 13]. The
tested synthetic compounds included eleven p-toluene-
sulfonyl-hydrazinothiazoles: 4-methyl-2-[2-(benzenesul-
fonyl)-N,N-diacetyl-hydrazino]-thiazole, C15H18N3O4S2
(1; m/z 368.07); 5-acetyl-4-methyl-2-[2-(benzenesulfo-
nyl)-hydrazino]-thiazole, C13H18N3O4S2 (2; m/z 344.07);
5-acetyl-4-methyl-2-[2-(benzenesulfonyl)-N,N-diacetyl-
hydrazino]-thiazole, C17H20N3O5S2 (3; m/z 410.08);
4-Phenyl-2-[2-(benzenesulfonyl)-N,N-diacetyl-hydrazino]-
thiazole, C22H24N3O2S2, (4; m/z 426.13); 5-bromo-4-
Chloromethyl-2-[2-(benzenesulfonyl)-N,N-diacetyl-hydraz
ino]-thiazole, C17H20BrClN3O2S2 (5; m/z 475.98); p-tolue-
nesulfonylthiosemicarbazide, C10H18N3O2S2 (6; m/z
276.08); 4-methyl-2-[2-(p-toluenesulfonyl)-N,N-diacetyl-
hydrazino]-thiazole, C16H20N3O4S2 (7; m/z 382.08); 4-
chloromethyl-2-[2-(p-toluenesulfonyl)-hydrazino]-thiazole,
C12H15ClN3O2S2 (8; m/z 332.02); 4-phenyl-2-[2-(p-toluene-
sulfonyl)-hydrazino]-thiazole, C17H18N3O2S2 (9; m/z
360.08); 5-acetyl-4-methyl-2-[2-(p-toluenesulfonyl)-hydra-
zino]-thiazole, C14H18N3O3S2 (10; m/z 340.07); 5-acetyl-4-
methyl-2-[2-(p-toluenesulfonyl)-N,N-diacetylhydrazino]-thi
azole, C18H22N3O5S2 (11; m/z 424.10) and hydrazino-
selenazoles: p-chloro-benzyliden-selenosemicarbazide,
C8H8ClN3Se (12; m/z 260.95); 4-methyl-2-[(4-chloro-
benzyliden)-hydrazinyl]-1,3-selenazole, C11H10ClN3Se
(13; m/z 298.97,); p-chloro-benzoyl-selenosemicarba-
zide C8H8ClN3OSe (14; m/z 276.95); 4-chloromethyl-2-
[(4-chlorobenziliden)-N-acetyl-hydrazinyl]-1,3-selenazole,
C13H11Cl2N3OSe (15; m/z 374.94); p-methoxy-benzyli-
den-selenosemicarbazide, C9H11N3OSe (16; m/z 257.00);
4-phenyl-[2-(4-metoxybenzyliden)-hydrazinyl]-1,3-selena-
zole, C17H15N3OSe (17; m/z 357.03); 4-chloromethyl-
[2-(2-phenyl-1,3-thiazolo-4-methylidene)-hydrazinyl]-1,
3-selenazole C16H19ClN4SSe (18; m/z 414.01); and 4-
methyl-5-acetyl-[2-(2-phenyl-1,3-thiazolo-4-methylid
ene)-hydrazinyl]-1,3-selenazole, C18H22N4OSSe (19; m/z
422.06). The synthesis of p-toluenesulfonyl-hydrazinothia-
zoles (1–11) [9] and hydrazinoselenazole (12–19) [11]
were previously reported. Their chemical structures are
summarized in Fig. 1.
Microbial strains and culture media
The studied microorganisms included sensitive and re-
sistant strains of Pseudomonas aeruginosa, Klebsiella
pneumoniae, Enterobacter aerogenes, Escherichia coli ob-
tained from the American Type Culture Collection
(ATCC) as well as clinical strains. Their bacterial feature
were previously reported [5, 14–16]. Nutrient agar were
used for the activation of the tested Gram-negative bac-
teria [17].
INT colorimetric assay for MIC and MBC determinations
The Minimum Inhibitory Concentration (MIC) determi-
nations on the tested bacteria were conducted using
rapid p-iodonitrotetrazolium chloride (INT) colorimetric
assay according to described methods [12] with some
modifications [18, 19]. The tested samples and RA were
first of all dissolved in DMSO/Mueller Hinton Broth
(MHB). The final concentration of DMSO was lower
than 2.5 % and does not affect the microbial growth
[20, 21]. The solution obtained was then added to
Mueller Hinton Broth, and serially diluted two fold (in
a 96- wells microplate). One hundred microlitre
(100 μL) of inoculum 1.5 x 106 CFU/mL prepared in
appropriate broth was then added [18, 19]. The plates
were covered with a sterile plate sealer, then agitated to
mix the contents of the wells using a plate shaker and
incubated at 37 °C for 18 h. The assay was repeated
thrice. Wells containing adequate broth, 100 μL of
inoculum and DMSO to a final concentration of 2.5 %
served as negative control. The MIC of samples was de-
tected after 18 h incubation at 37 °C, following addition
(40 μL) of 0.2 mg/mL of INT and incubation at 37 °C
for 30 min. Viable bacteria reduced the yellow dye to a
pink. MIC was defined as the sample concentration
that prevented the color change of the medium and ex-
hibited complete inhibition of microbial growth [12].
To evaluate the role of efflux pumps in the susceptibility
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of Gram-negative bacteria, compounds were tested in the




Compounds tested in the present study included p-
toluenesulfonyl-hydrazinothiazoles (1–11) [9] and
hydrazinoselenazoles (12–19) [11] previously synthe-
sized. They were tested for their antimicrobial activities
on a panel of 16 bacterial strains and the results are
summarized in Table 1.
Activity of p-toluenesulfonyl-hydrazinothiazoles
When they were tested alone at up to 256 mg/L, all
p-toluenesulfonyl-hydrazinothiazoles generally displayed
low or no antibacterial activity. However, compound 8
displayed a best activity with detectable MIC values
against 14/16 (87.5 %) bacterial strains (Table 1). This
compound was also more active than chloramphenicol
against E. aerogenes EA289, EA27 and K. pneumoniae
KP63. No detectable MIC value was recorded with
compounds 1, 2, 4, 5, 7, 9, 10 and 11 (Table 1).
Activity of hydrazinoselenazoles
The best activities were obtained with p-toluenesulfonyl-
hydrazinothiazoles; When they were tested at up to
256 mg/L, hydrazinoselenazole displayed selective anti-
bacterial activities. Compound 16 displayed MIC values
on 14/16 (87.5 %) tested bacteria whilst compounds 12,
13, 14, 15, 19 and were active respectively on 5/16




































































































































































Fig. 1 Chemical structures of the tested compounds
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Table 1 Minimal inhibitory concentration (MIC) of the studied samples on the tested microbial species
Samples E. coli strains and MIC* (mg/L) without PAβN (and with PAβN in parenthesis) % of PAβN
Modulating
effect
E. coli strains E. aerogenes strains K. pneumoniae P. aeruginosa
ATCC87 39 AG100 AG100A AG100A tet AG102 ATCC 13048 EACM64 EA289 EA294 EA298 EA27 ATCC 11296 KP55 KP63 PA01 PA124
p-Toluenesulfonylhydrazinothiazoles
1 i i i i i i i i i (64) i (256) i i i i i i 2/16 (12.5%)
2 i i i i i i i i i (64) i i i i i i i 1/16 (6.3%)
3 i (256) i i i i i i i i (64) i (256) i i 256 (256) i i i i 3/16 (18.8%)
4 i i i i i i i i i (64) i (32) i i i i i i 2/16 (12.5%)
5 i i i i i i i i i (64) i i i i i i i 1/16 (6.3%)
6 i i i i i i i i i (64) i i i 256 (256) i i i i 1/16 ( 6.3%)
7 i i i i i i i i i (64) i (256) i i (256) i (256) i i i 4/16 (25.0 %)























9 i i i i i i i i i (64) i i i i i i i 1/16 (6.25%)
10 i i i i i i i i i i i i i i i i 0/16 ( 0%)
11 i (256) i i i i i i i i i i i (256) i i (256) i i 3/16 ( 18.75%)
Hydrazinoselenazoles
12 256 (4) 256
(64)
i (4) i (16) i (16) i (256) i (16) 256
(128)
i (8) i (8) i (128) i (8) 128 (4) 128 (4) i i (256) 15/16
(93.8%)
13 256 (16) 128
(8)
128 (4) 128 (64) i i i i i (8) i (8) i 128 (64) 128
(16)
32 (8) i i 9/16 (56.3%)






15 i i i i i i i i i i i 256 (64) 32 (32) 128
(32)
i i (256) 3/16 (18.75 %)
16 64 (2) 256
(1)






17 i i i i (256) i i i i i (32) i (32) i i 256 (16) i (32) i i i (128) 6/16 (37.5%)
18 i i i (128) i i i i i i (16) i (32) i i (32) 256
(32)
i i i 5/16 (25.8 %)








i (128) 256 (16) 256
(32)
i (256) i i (256) 11/16
( 68.8%)




32 (4) 32 (2) 4 (1) 256 (8) i (128) 64 (16) 64
(16)




*The MIC of PAßN was 64 mg/L on AG100A and >256 mg/L for other E. coli , K. pneumoniae, P. aeruginosa and E. aerogenes strains















7/16 (43.8 %) and tested bacteria (Table 1). Compounds
12, 13, 14 and 15 were more active (lower MIC value)
than the reference drug (choramphenicol) on K. pneu-
moniae KP63. Compounds 12 was also more active than
the reference drug on E. aerogenes EA289 meanwhile
this was also the case with 16 against E. aerogenes
CM64, EA27, EA289, KP55 and KP63. Tested alone, the
lowest MIC value of 16 mg/L was obtained with com-
pound 16 against E. aerogenes ATCC13048, K. pneumoniae
ATCC11296 and KP55 (Table 1).
Role of efflux pumps in the susceptibility of tested
bacteria: identification of a PAβN-sensitive efflux in
addition to AcrAB-TolC pump
To evaluate the role of efflux on the susceptibility of
bacteria to the tested compounds, they were combined
with a well-known EPI, PAβN. The EPI was tested at
30 μg/mL, a concentration lower that it MIC value in
the studied bacteria. The results are summarized in
brackets in Table 1 (MIC of EPI is provided as footnote).
Apart from p-toluenesulfonyl-hydrazinothiazole 10,
PAβN improved the activity of all tested compounds on
at least one tested bacteria. The most important im-
provements of the activity of compounds in the presence
of PAβN were recorded with 12, 14, 16 and 19 on re-
spectively 15/16 (93.8 %), 16/16 (100 %), 16/16 (100 %)
and 11/16 (68.8 %) tested bacteria. With PAβN, the ac-
tivity of hydrazinoselenazoles 12, 13, 14 and 16 signifi-
cantly increased with MIC values below 10 mg/L
obtained respectively on 7/16 (43.8 %), 5/16 (31.3 %),
10/16 (62.5 %) and 16/16 (100 %) tested bacterial strains.
The lowest MIC value of 0.5 mg/L was recorded with
compounds 14 against E. coli ATCC8739 and KP55 as
well as 16 against E. aerogenes KP55 (Table 1). When
they were combined with EPI, hydrazinoselenazoles 12,
13, 14 and 16 were more active than choramphenicol
on at least two of the tested bacterial species.
Structure activity relationship and identification of
pharmacophoric moiety
When regarding the structure-activity relationship, it
appears that amongst the tested compounds, p-tolue-
nesulfonyl-hydrazinothiazoles were less active than
hydrazinoselenazoles. Within p-toluenesulfonyl-hydra-
zinothiazoles, it was also found that compound 8 scaf-
fold is the most active and that any modification of its
structure resulted to a decrease of antibacterial activ-
ity. Within hydrazinoselenazoles, it was also found that
compound 16 [active on 14/16 (87.5 %) and 16/16
(100 %) tested bacteria in the absence or presence of
EPI respectively; MIC values below 10 mg/L on all
tested bacteria in the presence of EPI and lowest MIC
value of 0.5 mg/L] can be considered as the phamaco-
phoric moiety. Within this moiety, the presence of a
free selenoamide is primordial for the antibacterial
activity, as compounds 12 and 14 (bearing a free sele-
noamide) were also very active, especially when they
were combined with EPI (Fig. 2). The presence of
chloride substituent seems to increase the affinity of
hydrazinoselenazole 12 and 14 to bacteria efflux


















The presence of chloride
improves the affinity to
bacterial efflux pumps
free selenoamide is important
for the antibacterial activity






Fig. 2 Representation of pharmacophoric groups detected in the tested compounds
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compounds 12 and 14 (with chloride substituent) were
much lower than that of 16 (with -OCH3 substituent).
Discussion
Bacterial multidrug resistance represents a major problem
in the treatment of infectious diseases. In the present
study, we tested a panel of bacterial strains including both
reference ATCC strains and MDR phenotypes expressing
active efflux pumps [4, 5, 22]. In fact, tripartite drug efflux
pumps, mainly those clinically reported as AcrAB–TolC
in Enterobacteriaceae or as MexAB–OprM in P. aerugi-
nosa tested in the present study, play a key role in
multidrug resistance of pathogenic Gram-negative bac-
teria [23, 24]. p-Toluenesulfonyl-hydrazinothiazoles and
hydrazinoselenazoles are synthetic compounds that previ-
ously displayed good anticancer, analgesic and anti-
inflammatory activities [8–11]. Herein, we investigated the
ability of such compounds to combat MDR Gram-
negative bacteria expressing active efflux pumps. As re-
sults, it was found that hydrazinoselenazoles were much
more active than p-toluenesulfonyl-hydrazinothiazoles.
However, all the tested chemicals were substrates of bac-
terial efflux pumps. Interestingly, when efflux pumps were
blocked by EPI, significant increase of the activity of three
compounds 12, 14 and 16 was observed. More import-
antly, the obtained activity was better than that of the ref-
erence drug chloramphenicol in many cases (Table 1),
suggesting that the three compounds can be used in com-
bination with PAβN to fight bacterial infections involving
MDR phenotypes. The antimicrobial activity of a com-
pound has been defined as significant when MIC is below
10 mg/L, moderate when 10 mg/L <MIC < 100 mg/L or
low when MIC > 100 mg/L [25, 26]. In this study, the MIC
values below 10 mg/L was noted with hydrazinoselena-
zoles 12, 14 and 16 on 43.8 %, 62.5 % and 100 % tested
bacterial strains when they were tested in the presence of
EPI, highlighting their possible use in combination with
PAβN in the control of MDR bacterial infections.
Regarding the involvement of MDR bacteria in treat-
ment failures and the re-emergence of infectious dis-
eases [1, 27, 28], these findings can be considered very
promising. In fact, Pseudomonas aeruginosa is an im-
portant nosocomial pathogen highly resistant to clinic-
ally used antibiotics, causing a wide spectrum of
infections and leading to substantial morbidity and
mortality [29] and was found sensitive to the three com-
pounds. MDR Enterobacteriaceae, including K. pneumo-
niae, E. aerogenes, P. stuartii and E. coli, have also been
classified as antimicrobial-resistant organisms of concern
in healthcare facilities [28, 30].
Conclusions
Regarding the medical importance of the studied mi-
croorganisms, the results obtained in this study
demonstrated that hydrazinoselenazoles are strong
source of inspiration in antibacterial drug discovery.
Thus, the present data showed that hydrazinoselena-
zoles 12, 14 and 16 are promising antibacterial
agents to combat MDR phenotypes, but are also sub-
strates of efflux pumps. They should therefore be
combined with an EPI to combat MDR phenotypes.
We also found that compound 16 skeleton was the
pharmacophoric moiety of the tested hydrazinosele-
nazoles and that the presence of a free selenoamide
scaffold is necessary for their antibacterial activity.
However, more compounds should be further synthe-
sized to fully investigate the structure-activity rela-
tionship for this series of hydrazinoselenazoles.
Toxicological studies will also be performed to





















1,3-selenazole; ATCC: American Type Culture Collection; CFU: Colony
forming unit; DMSO: dimethysulfoxide; EPI: Efflux pumps inhibitor; INT: p-
iodonitrotetrazolium chloride; MDR: Multidrug resistant; MHB: Mueller Hinton
Broth; MIC: Minimal inhibitory concentration; PAβN: Phenylalanine arginine
β-naphthylamide; RA: Reference antibiotic.
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